Sarepta Therapeutics, Inc.
SRPT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $2 | $1 | $1 | $1 |
| % Growth | 53% | 33.3% | 32.9% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $2 | $1 | $1 | $1 |
| % Margin | 83.2% | 87.9% | 85% | 86.2% |
| R&D Expenses | $1 | $1 | $1 | $1 |
| G&A Expenses | $1 | $0 | $0 | $0 |
| SG&A Expenses | $1 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1 | $1 | $1 | $1 |
| Operating Income | $0 | -$0 | -$1 | -$0 |
| % Margin | 11.5% | -21.5% | -57.5% | -65.5% |
| Other Income/Exp. Net | $0 | -$0 | -$0 | $0 |
| Pre-Tax Income | $0 | -$1 | -$1 | -$0 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | $0 | -$1 | -$1 | -$0 |
| % Margin | 12.4% | -43.1% | -75.4% | -59.7% |
| EPS | 2.47 | -5.8 | -8.03 | -5.15 |
| % Growth | 142.6% | 27.8% | -55.9% | – |
| EPS Diluted | 2.34 | -5.8 | -8.03 | -5.15 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | -$0 | -$1 | -$0 |
| % Margin | 16.7% | -36.5% | -63.8% | -45.2% |